探讨luminal B型乳腺癌骨转移患者的临床特点和预后情况。

收集2004年1月至2012年1月郑州大学人民医院诊治的luminal B型乳腺癌骨转移患者128例，其中75例人表皮生长因子受体（HER）-2阴性，53例HER-2阳性，回顾性分析其临床特点和预后。

两组患者在骨转移确诊年龄、原发肿瘤大小、腋窝淋巴结转移数目和术后骨转移发生的时间方面的差异有统计学意义（χ²=4.477、6.927、12.209、11.222，P=0.034、0.023、0.002、0.004）。Luminal B型HER-2阴性乳腺癌患者发生骨转移后的中位生存时间为29.8个月，5年生存率22.7%，HER-2阳性乳腺癌患者分别为27.1个月和20.7%，两组患者骨转移后的生存时间差异无统计学意义（χ²=0.398，P=0.528）。

Luminal B型HER-2阳性比luminal B型HER-2阴性乳腺癌骨转移患者更具有发病年龄大、原发肿瘤直径大、腋窝淋巴结转移数目多、术后发生骨转移时间早等特点，但两种类型患者的预后无显著差异。

To investigate the clinical characteristics and prognosis of luminal B subtype breast cancer patients with bone metastases.

The data of one hundred and twenty-eight cases of luminal B subtype breast cancer with bone metastases were collected from January 2004 to January 2012, 75 of whom were HER-2 negative and 53 were HER-2 positive. The clinical characteristics and prognosis were analyzed retrospectively.

There were statistically significant differences in the confirmed age of bone metastases, the size of the primary tumor, the number of axillary lymph node metastases, and the time of postoperative bone metastasis between the two groups (χ²=4.477, 6.927, 12.209, 11.222, P=0.034, 0.023, 0.002, 0.004). The median survival time and 5-year survival rate of luminal B HER-2 negative type breast cancer patients after bone metastases were 29.8 months and 22.7%, and 27.1 months and 20.7% respectively for luminal B HER-2 positive type breast cancer patients. There was no significant difference in survival time after bone metastasis between the two groups (χ²=0.398, P=0.528).

Luminal B HER-2 positive type is more common than luminal B HER-2 negative breast cancer patients with bone metastasis in older age, larger diameter of primary tumor, more axillary lymph node metastasis, and earlier bone metastasis after surgery. There is no significant difference in the prognosis of two type patients.